安徽医学
安徽醫學
안휘의학
Anhui Medical Journal
2015年
11期
1384-1386
,共3页
舍曲林%脑卒中%抑郁症%白细胞介素-6%白细胞介素-1β%肿瘤坏死因子-α
捨麯林%腦卒中%抑鬱癥%白細胞介素-6%白細胞介素-1β%腫瘤壞死因子-α
사곡림%뇌졸중%억욱증%백세포개소-6%백세포개소-1β%종류배사인자-α
Sertraline%Stroke%Depression%IL-6%IL-1β%TNF-α
目的：观察舍曲林治疗脑卒中患者抑郁的疗效及对 IL-6、IL-1β、TNF-α的影响，探讨其临床适用性。方法选择2011年1月至2014年10月收治的脑卒中患者150例，简单随机分为试验组和对照组各75例，两组均在常规治疗的基础上，试验组予口服舍曲林，对照组予阿米替林治疗。采用汉密顿抑郁量表（HAMD）、抑郁自评量表（SDS）评估治疗前后抑郁情况，观察两组患者血清白细胞介素-6（IL-6）、白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）水平及不良反应发生情况。结果试验组和对照的总有效率分别为92.0%和70.7%，差异有统计学意义（P <0.05）；两组患者治疗前 HAMD、SDS 评分比较，差异均无统计学意义（P >0.05），治疗后两组评分均较治疗前降低（P <0.05），但试验组优于对照组，差异有统计学意义（P <0.05）；两组患者治疗前 IL-6、IL-1β、TNF-α血清水平相当，差异无统计学意义（P >0.05），治疗后各细胞因子水平均有所下降（P <0.05），但试验组较治疗组下降更为显著，差异有统计学意义（P <0.05）；两组的不良反应发生情况大致相当，差异无统计学意义（P <0.05）。结论舍曲林可以有效改善脑卒中患者的抑郁症状及血清 IL-6、IL-1β、TNF-α水平。
目的：觀察捨麯林治療腦卒中患者抑鬱的療效及對 IL-6、IL-1β、TNF-α的影響，探討其臨床適用性。方法選擇2011年1月至2014年10月收治的腦卒中患者150例，簡單隨機分為試驗組和對照組各75例，兩組均在常規治療的基礎上，試驗組予口服捨麯林，對照組予阿米替林治療。採用漢密頓抑鬱量錶（HAMD）、抑鬱自評量錶（SDS）評估治療前後抑鬱情況，觀察兩組患者血清白細胞介素-6（IL-6）、白細胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）水平及不良反應髮生情況。結果試驗組和對照的總有效率分彆為92.0%和70.7%，差異有統計學意義（P <0.05）；兩組患者治療前 HAMD、SDS 評分比較，差異均無統計學意義（P >0.05），治療後兩組評分均較治療前降低（P <0.05），但試驗組優于對照組，差異有統計學意義（P <0.05）；兩組患者治療前 IL-6、IL-1β、TNF-α血清水平相噹，差異無統計學意義（P >0.05），治療後各細胞因子水平均有所下降（P <0.05），但試驗組較治療組下降更為顯著，差異有統計學意義（P <0.05）；兩組的不良反應髮生情況大緻相噹，差異無統計學意義（P <0.05）。結論捨麯林可以有效改善腦卒中患者的抑鬱癥狀及血清 IL-6、IL-1β、TNF-α水平。
목적：관찰사곡림치료뇌졸중환자억욱적료효급대 IL-6、IL-1β、TNF-α적영향，탐토기림상괄용성。방법선택2011년1월지2014년10월수치적뇌졸중환자150례，간단수궤분위시험조화대조조각75례，량조균재상규치료적기출상，시험조여구복사곡림，대조조여아미체림치료。채용한밀돈억욱량표（HAMD）、억욱자평량표（SDS）평고치료전후억욱정황，관찰량조환자혈청백세포개소-6（IL-6）、백세포개소-1β（IL-1β）、종류배사인자-α（TNF-α）수평급불량반응발생정황。결과시험조화대조적총유효솔분별위92.0%화70.7%，차이유통계학의의（P <0.05）；량조환자치료전 HAMD、SDS 평분비교，차이균무통계학의의（P >0.05），치료후량조평분균교치료전강저（P <0.05），단시험조우우대조조，차이유통계학의의（P <0.05）；량조환자치료전 IL-6、IL-1β、TNF-α혈청수평상당，차이무통계학의의（P >0.05），치료후각세포인자수평균유소하강（P <0.05），단시험조교치료조하강경위현저，차이유통계학의의（P <0.05）；량조적불량반응발생정황대치상당，차이무통계학의의（P <0.05）。결론사곡림가이유효개선뇌졸중환자적억욱증상급혈청 IL-6、IL-1β、TNF-α수평。
Objective To discuss the efficacy of sertraline in the treatment of depression in stroke patients and its effect on IL-6,IL-1β,TNF-α and its clinical applicability. Methods 150 cases of stroke patients ever treated in our hospital from Jan 2011 to Oct 2014 were selected,and were equally,randomly divided into experiment group and control group. Besides the conventional therapy of stroke,the exper-iment group was given sertraline,while the control group receiving amitriptyline. The depression status before and after treatment in the two groups were evaluated with HAMD and SDS scale,and the serum IL-6,IL-1β,TNF-α levels and adverse reactions were also observed and recorded. Results The total effective rate in the experiment group and the control group were 92% and 70. 7% ,respectively,and the difference between them was statistically significant(P < 0. 05). There was no significant difference in HAMD and SDS scores before treat-ment between the two groups(P > 0. 05),but after treatment,decrease of HAMD and SDS scores in the experiment group was better than that in the control group with significant difference(P < 0. 05). The serum levels of IL-6,IL-1β,TNF-α before treatment in both groups were equivalent in general,with no significant difference(P > 0. 05),and the results of these cytokines after treatment decreased totally,but decrease of the experiment group were also better than that of the control group with significant difference(P < 0. 05). The adverse reaction between the two groups was roughly the same,with no statistical significance(P > 0. 05). Conclusion Sertraline could effectively improve the depressive symptoms in patients with stroke and serum levels of IL-6,IL-1β,TNF-α.
